A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Mirza MR, Bergmann TK, Mau-S?rensen M, Christensen RD, ?vall-Lundqvist E, Birrer MJ, J?rgensen M, Roed H, Malander S, Nielsen F, Lassen U, Br?sen K, Bj?rge L, M?enp?? J. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemother Pharmacol. 2019 10; 84(4):791-798.